JP2012508169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508169A5 JP2012508169A5 JP2011534633A JP2011534633A JP2012508169A5 JP 2012508169 A5 JP2012508169 A5 JP 2012508169A5 JP 2011534633 A JP2011534633 A JP 2011534633A JP 2011534633 A JP2011534633 A JP 2011534633A JP 2012508169 A5 JP2012508169 A5 JP 2012508169A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- humanized anti
- seq
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 239000000032 diagnostic agent Substances 0.000 claims 8
- 229940039227 diagnostic agent Drugs 0.000 claims 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 4
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 4
- 108700020796 Oncogene Proteins 0.000 claims 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 4
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 4
- 208000037914 B-cell disorder Diseases 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- -1 CD66 (ad) Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 2
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims 2
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 claims 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 102000043276 Oncogene Human genes 0.000 claims 2
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 2
- 102100035194 Placenta growth factor Human genes 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 102100035721 Syndecan-1 Human genes 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 102000007000 Tenascin Human genes 0.000 claims 2
- 108010008125 Tenascin Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002961 echo contrast media Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 102220040238 rs116211453 Human genes 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/266,999 US7902338B2 (en) | 2003-07-31 | 2008-11-07 | Anti-CD19 antibodies |
| US12/266,999 | 2008-11-07 | ||
| PCT/US2009/061666 WO2010053716A1 (en) | 2008-11-07 | 2009-10-22 | Improved anti-cd19 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117532A Division JP5951850B2 (ja) | 2008-11-07 | 2015-06-10 | 改良された抗ｃｄ１９抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508169A JP2012508169A (ja) | 2012-04-05 |
| JP2012508169A5 true JP2012508169A5 (OSRAM) | 2012-11-15 |
| JP5762965B2 JP5762965B2 (ja) | 2015-08-12 |
Family
ID=42153175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534633A Active JP5762965B2 (ja) | 2008-11-07 | 2009-10-22 | 改良された抗ｃｄ１９抗体 |
| JP2015117532A Active JP5951850B2 (ja) | 2008-11-07 | 2015-06-10 | 改良された抗ｃｄ１９抗体 |
| JP2016114443A Pending JP2017019765A (ja) | 2008-11-07 | 2016-06-08 | 改良された抗ｃｄ１９抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117532A Active JP5951850B2 (ja) | 2008-11-07 | 2015-06-10 | 改良された抗ｃｄ１９抗体 |
| JP2016114443A Pending JP2017019765A (ja) | 2008-11-07 | 2016-06-08 | 改良された抗ｃｄ１９抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US7902338B2 (OSRAM) |
| EP (1) | EP2352523B1 (OSRAM) |
| JP (3) | JP5762965B2 (OSRAM) |
| CN (1) | CN102209556B (OSRAM) |
| AU (1) | AU2009311461B2 (OSRAM) |
| CA (1) | CA2742254A1 (OSRAM) |
| IL (1) | IL212701A (OSRAM) |
| WO (1) | WO2010053716A1 (OSRAM) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US7608425B2 (en) * | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| WO2010054288A2 (en) * | 2008-11-07 | 2010-05-14 | National Jewish Health | Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs") |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| WO2010117059A1 (ja) * | 2009-04-10 | 2010-10-14 | 国立大学法人大阪大学 | 形質細胞の腫瘍性増殖をきたす疾患の治療薬 |
| CN103154242B (zh) * | 2010-07-06 | 2015-09-30 | 诺华股份有限公司 | 诺如病毒衍生的免疫原性组合物和方法 |
| PL2744826T3 (pl) | 2011-08-16 | 2022-05-30 | Morphosys Ag | Terapia skojarzona przeciwciałem anty-cd19 i analogiem puryny |
| KR20200058583A (ko) | 2011-08-16 | 2020-05-27 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| BR112014012667A2 (pt) * | 2011-12-22 | 2018-10-09 | F Hoffmann-La Roche Ag | vetor de expressão, usos de vetor de expressão, método de transfecção de células eucarióticas, uso de método, uso de célula, métodos de produção de anticorpos e método de transfecção |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014080251A1 (en) | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| BR112015013444B1 (pt) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CA2907397C (en) | 2013-03-15 | 2022-11-22 | Anthrogenesis Corporation | Modified t lymphocytes |
| EP3107577B1 (en) | 2014-02-21 | 2024-03-20 | IBC Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
| PT3122757T (pt) | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Ligantes carregados e as suas utilizações em conjugação |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| CN105837689B (zh) * | 2015-01-13 | 2020-06-19 | 博生吉安科细胞技术有限公司 | 抗cd19单克隆抗体及其制备方法 |
| EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| HUE046328T2 (hu) | 2015-05-26 | 2020-03-30 | Morphosys Ag | CD19 elleni ellenanyag és Bruton-féle tirozin-kináz gátlójának kombinációja és a kombináció alkalmazásai |
| WO2016201350A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Combination therapy for treatment of cancer |
| WO2015151078A2 (en) | 2015-06-15 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Hydrophilic linkers for conjugation |
| WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CN107735104B (zh) | 2015-06-25 | 2022-05-03 | 免疫医疗公司 | 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善 |
| EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| CN108449940B (zh) | 2015-07-12 | 2021-06-08 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
| EP4516319A3 (en) | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PT3916392T (pt) | 2016-05-30 | 2024-06-04 | Incyte Corp | Métodos para prever o benefício terapêutico da terapia anti-cd19 nos pacientes |
| HRP20210945T1 (hr) | 2016-06-27 | 2021-09-17 | Morphosys Ag | Formulacije protutijela anti-cd19 |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN111848801B (zh) * | 2016-09-06 | 2022-10-11 | 上海吉倍生物技术有限公司 | 一种抗cd19抗体及其制备方法和用途 |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| EP4092049A1 (en) | 2016-10-20 | 2022-11-23 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| LT3532098T (lt) | 2016-10-28 | 2021-06-25 | Morphosys Ag | Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas |
| CN110099682B (zh) | 2016-11-14 | 2023-03-31 | 杭州多禧生物科技有限公司 | 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN108610420B (zh) * | 2016-12-13 | 2023-09-26 | 科济生物医药（上海）有限公司 | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 |
| WO2018220040A1 (en) | 2017-05-31 | 2018-12-06 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| DE102017215966A1 (de) * | 2017-09-11 | 2019-03-14 | BSH Hausgeräte GmbH | Haushaltsgerät mit Temperaturdetektor |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| JOP20200292A1 (ar) | 2018-05-16 | 2020-11-15 | Stichting Vumc | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان |
| BR112020023846A2 (pt) | 2018-05-23 | 2021-04-13 | Adc Therapeutics Sa | Adjuvante molecular |
| CN108659128B (zh) * | 2018-05-30 | 2021-06-04 | 福州迈新生物技术开发有限公司 | 抗cd19蛋白的单克隆抗体及其细胞株、制备方法和应用 |
| CN109180798B (zh) * | 2018-09-04 | 2020-10-27 | 武汉原生药谷生物医药科技有限公司 | 一种增强型治疗性抗体及其应用 |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN111253487B (zh) * | 2018-12-03 | 2024-02-02 | 广东东阳光药业股份有限公司 | Cd19抗体及其应用 |
| MA55794A (fr) | 2019-05-03 | 2022-03-09 | Morphosys Ag | Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| WO2021034952A1 (en) * | 2019-08-19 | 2021-02-25 | Elpis Biopharmaceuticals | Anti-cd19 antibodies and uses thereof |
| BR112022004776A2 (pt) * | 2019-09-16 | 2022-06-21 | Opsidio Llc | Anticorpos anti-fator de células-tronco e métodos para uso dos mesmos |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| KR20220103969A (ko) | 2019-10-31 | 2022-07-25 | 모르포시스 아게 | 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법 |
| AU2020372646A1 (en) | 2019-10-31 | 2022-05-12 | Incyte Corporation | Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells |
| MX2022010549A (es) | 2020-02-26 | 2022-11-16 | Biograph 55 Inc | Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras. |
| CN119143877A (zh) * | 2020-03-03 | 2024-12-17 | 成都百利多特生物药业有限责任公司 | 抗cd19抗体及其使用和制备方法 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2023530499A (ja) | 2020-06-22 | 2023-07-18 | モルフォシス・アーゲー | 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法 |
| TW202229349A (zh) | 2020-10-06 | 2022-08-01 | 美商山可爾股份有限公司 | 用於治療包括全身性紅斑性狼瘡(sle)的自體免疫疾病之生物標記、方法及組合物 |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
| BR112023010885A2 (pt) | 2020-12-04 | 2023-10-03 | Incyte Corp | Terapia de combinação de anti-cd19 |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| WO2023198744A1 (en) | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Therapeutic t cell product |
| EP4572756A1 (en) | 2022-08-17 | 2025-06-25 | Incyte Corporation | Therapy comprising anti-cd19 antibody and ezh2 modulators |
| US12173081B2 (en) | 2023-03-21 | 2024-12-24 | Biograph 55, Inc. | CD19/CD38 multispecific antibodies |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861511B1 (en) | 1986-06-04 | 2005-03-01 | Bayer Corporation | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2033347C (en) | 1989-06-02 | 2000-02-29 | James E. Hildreth | Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore |
| US5270196A (en) | 1989-10-20 | 1993-12-14 | Bristol-Myers Squibb Company | Arylsulfatase from streptomyces |
| US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
| FR2676058B1 (fr) | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
| US5854416A (en) | 1991-11-14 | 1998-12-29 | The United States Of America As Represented By The Department Of Health And Human Services | Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| DE69333348T2 (de) | 1992-03-09 | 2004-09-16 | San Diego Regional Cancer Center, San Diego | Anti-idiotypischer Antikörper und seine Verwendung zur Diagnose und Therapie bei HIV-bezogenen Krankheiten |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
| US6100389A (en) | 1995-04-21 | 2000-08-08 | Human Genome Sciences, Inc. | Polynucleotides encoding a human chemotactic protein |
| WO1996004925A1 (en) | 1994-08-12 | 1996-02-22 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
| US6537764B1 (en) | 1995-01-19 | 2003-03-25 | Children's Medical Center Corporation | Method of identifying inhibitors of C—C chemokine receptor 3 |
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| US5798554A (en) | 1995-02-24 | 1998-08-25 | Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno | MOS-technology power device integrated structure and manufacturing process thereof |
| EP0835134A1 (en) | 1995-05-17 | 1998-04-15 | Regents Of The University Of Minnesota | Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies |
| US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
| US5646298A (en) | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
| US6174992B1 (en) | 1997-03-21 | 2001-01-16 | Human Genome Sciences, Inc. | Human endometrial specific steroid-binding factor I, II and III |
| US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6004780A (en) | 1996-03-26 | 1999-12-21 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US6043348A (en) | 1996-11-13 | 2000-03-28 | Lawman; Michael J. P. | Antibody recognizing a small subset of human hematopoietic cells |
| US6605699B1 (en) | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
| US6046031A (en) | 1997-01-21 | 2000-04-04 | Human Genome Sciences, Inc. | Metalloproteinases |
| ES2284199T5 (es) | 1997-01-28 | 2011-11-14 | Human Genome Sciences, Inc. | Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l). |
| US6919433B2 (en) | 1997-03-14 | 2005-07-19 | Human Genome Sciences, Inc. | Antibodies to protein HPMBQ91 |
| US6951924B2 (en) | 1997-03-14 | 2005-10-04 | Human Genome Sciences, Inc. | Antibodies against secreted protein HTEBYII |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| US6861227B2 (en) | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| WO1999065523A1 (en) | 1998-06-15 | 1999-12-23 | Altarex Corp. | Immunotherapeutic composition and method for the treatment of prostate cancer |
| EP1141376A4 (en) | 1998-12-23 | 2002-03-13 | Human Genome Sciences | PEPTIDOGLYCANE RECOGNITION PROTEINS |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| US20020002270A1 (en) | 1999-06-16 | 2002-01-03 | Raymond P. Zinkowski | Purified antigen for alzheimer's disease, and methods of obtaining and using same |
| US6964854B1 (en) | 1999-07-13 | 2005-11-15 | Science & Technology Corporation | Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis |
| US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US6994976B1 (en) | 1999-11-19 | 2006-02-07 | Tittle Thomas V | Tr3-specific binding agents and methods for their use |
| US6319675B1 (en) | 1999-11-24 | 2001-11-20 | Millennium Pharmaceuticals, Inc. | Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor |
| US6835549B2 (en) | 2000-02-24 | 2004-12-28 | University Of Medicine & Dentistry Of New Jersey | Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma |
| EP1265929B1 (en) | 2000-03-23 | 2009-07-08 | Genentech, Inc. | Anti-c2/c2a inhibitors of complement activation |
| JP2004500863A (ja) | 2000-06-06 | 2004-01-15 | ブリストル−マイヤーズ スクイブ カンパニー | 免疫調節に有用なｂ７関連核酸およびポリペプチド |
| AU2001278129A1 (en) | 2000-07-31 | 2002-02-13 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Specific binding agents for kshv vil-6 that neutralize a biological activity |
| US7060802B1 (en) | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| AU2001296483B2 (en) | 2000-10-02 | 2006-02-16 | Oklahoma Medical Research Foundation | Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor |
| UY27087A1 (es) | 2001-01-05 | 2002-06-20 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6824778B2 (en) | 2001-04-23 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Prophylactic and therapeutic monoclonal antibodies |
| US6962813B2 (en) | 2001-05-21 | 2005-11-08 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
| US7049060B2 (en) | 2001-11-05 | 2006-05-23 | Ortho-Clinical Diagnostics, Inc. | HCV anti-core monoclonal antibodies |
| EP2295468B1 (en) | 2002-02-14 | 2015-07-08 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| JP4472351B2 (ja) | 2002-03-01 | 2010-06-02 | イミューノメディクス、インコーポレイテッド | インターナライジング抗ｃｄ７４抗体およびその使用方法 |
| MXPA04012656A (es) | 2002-06-14 | 2005-08-15 | Immunomedics Inc | Anticuerpo hpam4 monoclonal humanizado. |
| AU2004205684A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| JP2006517963A (ja) | 2003-01-28 | 2006-08-03 | シェーリング コーポレイション | 形質細胞様樹状細胞についての抗体特異性 |
| JP4733635B2 (ja) * | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| WO2007002223A2 (en) * | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| KR101456728B1 (ko) * | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| WO2008081331A2 (en) * | 2006-12-29 | 2008-07-10 | Sinomab Bioscience Limited | Enhancing the level of antibody expression by framework re-engineering |
-
2008
- 2008-11-07 US US12/266,999 patent/US7902338B2/en not_active Expired - Lifetime
-
2009
- 2009-10-22 AU AU2009311461A patent/AU2009311461B2/en active Active
- 2009-10-22 EP EP09825205.9A patent/EP2352523B1/en active Active
- 2009-10-22 CA CA2742254A patent/CA2742254A1/en not_active Abandoned
- 2009-10-22 CN CN200980144442.0A patent/CN102209556B/zh active Active
- 2009-10-22 JP JP2011534633A patent/JP5762965B2/ja active Active
- 2009-10-22 WO PCT/US2009/061666 patent/WO2010053716A1/en not_active Ceased
-
2010
- 2010-10-19 US US12/907,262 patent/US8147831B2/en not_active Expired - Lifetime
-
2011
- 2011-05-05 IL IL212701A patent/IL212701A/en active IP Right Grant
-
2012
- 2012-02-16 US US13/398,214 patent/US8337840B2/en not_active Expired - Lifetime
- 2012-11-19 US US13/680,713 patent/US8486395B2/en not_active Expired - Fee Related
-
2013
- 2013-06-17 US US13/919,512 patent/US8624001B1/en not_active Expired - Lifetime
- 2013-11-22 US US14/087,799 patent/US9056917B2/en not_active Expired - Lifetime
-
2015
- 2015-05-08 US US14/707,174 patent/US20150252110A1/en not_active Abandoned
- 2015-06-10 JP JP2015117532A patent/JP5951850B2/ja active Active
-
2016
- 2016-06-08 JP JP2016114443A patent/JP2017019765A/ja active Pending
- 2016-06-27 US US15/193,583 patent/US9605071B2/en not_active Expired - Fee Related
-
2017
- 2017-02-14 US US15/432,509 patent/US20170152315A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508169A5 (OSRAM) | ||
| JP7730764B2 (ja) | アンタゴニスト抗ｃｄ７抗体 | |
| TWI425005B (zh) | 與４－１ｂｂ結合之分子類 | |
| JP2006500904A5 (OSRAM) | ||
| CN109022465B (zh) | 多肽构建体及其用途 | |
| CN113286819B (zh) | 抗btn3a抗体及其在治疗癌症或感染性病症中的用途 | |
| CA2478012A1 (en) | Internalizing anti-cd74 antibodies and methods of use | |
| JP7339948B2 (ja) | モノクローナル抗体およびその使用法 | |
| TW200918558A (en) | Humanized anti-CXCR5 antibodies, derivatives thereof and their use | |
| TW201420600A (zh) | 抗－間皮素結合蛋白質 | |
| JP2014508511A5 (OSRAM) | ||
| EP3083688A2 (en) | Human anti-cd40 human antibodies | |
| JP2017019765A (ja) | 改良された抗ｃｄ１９抗体 | |
| WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| CN112105373B (zh) | 治疗b型肝炎病毒感染的方法 | |
| KR20170020477A (ko) | 인터페론 알파 및 오메가 항체 길항제 | |
| WO2020055932A2 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| JP7686614B2 (ja) | 癌の治療に用いるための抗ｃｄ１３７抗原結合分子 | |
| JP2019214621A (ja) | 抗ホスホリパーゼｄ４抗体を含む医薬 | |
| US20210230262A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| US20210322547A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| US11130805B2 (en) | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist | |
| US20210290677A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| CN120077067A (zh) | B7-h3抗原结合分子 | |
| TW202340254A (zh) | 抗btla抗體及其於治療癌症之用途 |